Colmenarejo G, Alvarez-Pedraglio A, Lavandera J L
Structural Chemistry Department, GlaxoSmithKline, Parque Tecnológico de Madrid, E-28760 Tres Cantos, Madrid, Spain.
J Med Chem. 2001 Dec 6;44(25):4370-8. doi: 10.1021/jm010960b.
Models to predict binding affinities to human serum albumin (HSA) should be very useful in the pharmaceutical industry to speed up the design of new compounds, especially as far as pharmacokinetics is concerned. We have experimentally determined through high-performance affinity chromatography the binding affinities to HSA of 95 diverse drugs and druglike compounds. These data have allowed us the derivation of quantitative structure-activity relationship models to predict binding affinities to HSA of new compounds on the basis of their structure. Simple linear, one-variable models have been derived for specific families of compounds (r(2) > or = 0.80; q(2) > or = 0.62): beta-adrenergic antagonists, steroids, COX inhibitors, and tricyclic antidepressants. Also, global models have been derived to be applicable to the whole medicinal chemical space by using the full database of HSA binding constants described above. For this aim, a genetic algorithm has been used to exhaustively search and select for multivariate and nonlinear equations, starting from a large pool of molecular descriptors. The resulting models display good fits to the experimental data (r(2) > or = 0.78; LOF < or = 0.12). In addition, both internal (cross validation and randomization) and external validation tests have demonstrated that these models have good predictive power (q(2) > or = 0.73; PRESS/SSY < or = 0.23; r(2) > or = 0.82 for the external set). Statistical analysis of the equation populations indicates that hydrophobicity (as measured by the ClogP) is the most important variable determining the binding extent to HSA. In addition, structural factors (especially the topological (6)chi(ring) index and some Jurs descriptors) also frequently appear as descriptors in the best equations. Therefore, binding to HSA turns out to be determined by a combination of hydrophobic forces together with some modulating shape factors. This agrees with X-ray structures of HSA alone or bound to ligands, where the binding pockets of both sites I and II are composed mainly of hydrophobic residues.
预测与人类血清白蛋白(HSA)结合亲和力的模型在制药行业中对于加速新化合物的设计非常有用,尤其是在药代动力学方面。我们通过高效亲和色谱法实验测定了95种不同药物及类药物化合物与HSA的结合亲和力。这些数据使我们能够推导定量构效关系模型,以便根据新化合物的结构预测其与HSA的结合亲和力。针对特定化合物家族(r(2)≥0.80;q(2)≥0.62)推导了简单的线性单变量模型:β-肾上腺素能拮抗剂、类固醇、COX抑制剂和三环类抗抑郁药。此外,通过使用上述HSA结合常数的完整数据库,还推导了适用于整个药物化学空间的全局模型。为此,使用遗传算法从大量分子描述符中进行详尽搜索并选择多变量和非线性方程。所得模型与实验数据拟合良好(r(2)≥0.78;LOF≤0.12)。此外,内部(交叉验证和随机化)和外部验证测试均表明这些模型具有良好的预测能力(q(2)≥0.73;PRESS/SSY≤0.23;外部集的r(2)≥0.82)。对方程总体的统计分析表明,疏水性(以ClogP衡量)是决定与HSA结合程度的最重要变量。此外,结构因素(尤其是拓扑(6)χ(环)指数和一些朱尔斯描述符)在最佳方程中也经常作为描述符出现。因此,与HSA的结合是由疏水力与一些调节形状因素共同决定的。这与单独的HSA或与配体结合的HSA的X射线结构一致,其中位点I和II的结合口袋主要由疏水残基组成。